|
|
Temozolomide
for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate
use Program in Belgium
Els Everaert, Bart Neyns,
Eric Joosens, Theo Strauven, Fabrice Branle, Johan
Menten
Medical Oncology, UZ-Gasthuisberg KUL,
Katholieke Universiteit Leuven, Leuven [E.E.*]. Medical Oncology, Oncology Center AZ-VUB, Vrije
Universiteit Brussel, Brussels; AZ-VUB, Laarbeeklaan 101 B-1090 Brussels,
Belgium; Tel.: +32-2-477-64-15; Fax: +32-2-477-62-10; E-mail: Bart.Neyns@pandora.be
[B.N.*]. Medical Oncology, AZ Middelheim [E.J.]. Neurology, AZ
Sint-Augustinus Wilrijk, Antwerp [T.S.]. Medical Oncology, Hôpital Erasme ULB, Université Libre de Bruxelles, Brussels [F.B.].Radiation
Oncology, UZ-Gasthuisberg KUL, Katholieke Universiteit Leuven, Leuven, Belgium
[J.M.]. (*Both authors contributed equally to this article.)
Temozolomide
(TMZ) has demonstrated activity and acceptable toxicity for the treatment of
recurrent high-grade gliomas in prospective phase II studies.
Limited information is available on TMZ when prescribed outside a clinical
trial.
We conducted a retrospective study to evaluate the activity and safety of TMZ
that was prescribed for the treatment of recurrent glioma in the context of a
compassionate use program in Belgium.
Data were obtained on 117 adult patients (from five hospitals) who received TMZ
as first or second line chemotherapy.
The recommended starting dose of TMZ was 200 mg/m2 ×5d
q28d for chemonaive patients and 150 mg/m2 ×5d
q28d for pre-treated patients. –123)
and the median overall survival was 215 days (95% CI: 161–269).
In multivariate analysis a ‘deep
localization’
of the glioma (as opposed to a cortico-subcortical localization) and ‘the
preceding history of a low-grade glioma’
were respectively identified as a negative and positive independent prognostic
variable for survival.
No significant difference in terms of response or median survival was observed
between patients with anaplastic astrocytoma or oligo-astrocytoma and chemonaive
glioblastoma multiforme.
This retrospective study indicates that the reported activity and toxicity
profile of TMZ for the treatment of patients with recurrent glioma is
reproducible outside the setting of a prospective clinical trial.
Keywords: astrocytoma,
brain, chemotherapy, glioblastoma, oligodendroglioma, recurrent, temozolomide,
tumor
Copyright ©
2004 Kluwer Academic Publishers.
All rights reserved
Source: http://ipsapp009.kluweronline.com/IPS/content/ext/x/J/5042/I/123/A/1/abstract.htm
|
